ANXA2 and central nervous system cancer: Additionally, in GSE4412 dataset, the OS of glioma patients with high expression of ANXA2 and its pseudogenes were noticeably worse than that with low expression (P=0.0058, P=0.0347, P=0.0019, P=0.0088, respectively; Figure 5C), and even more significant results were obtained from GSE43378 datasets (P<0.0001, P=0.0120, P<0.0001, P=0.1323, Figure 5D).